A Corcept Director Holds 1.5 Million Shares Through a 50% Crash and Rebound
This sale was executed under a Rule 10b5-1 trading plan adopted in March, while the stock has gained 25% over the past year.
Overview
James N. Wilson, a director at Corcept Therapeutics Incorporated (NASDAQ:CORT), sold 10,000 shares of the company on July 15, 2026, according to an SEC Form 4 filing.
Transaction value based on SEC Form 4 weighted average sale price ($88.30); post-transaction value based on July 15, 2026 market close ($89.57).
Details
Corcept Therapeutics is a specialty pharmaceutical company with a market capitalization of $9.6 billion, generating TTM revenues of $769.1 million and net income of $47.3 million. The company maintains a focused pipeline strategy centered on its commercial flagship Korlym, which addresses a significant unmet medical need in endogenous Cushing's syndrome treatment, positioning it as a specialized player within the pharmaceutical sector with demonstrated profitability and revenue growth momentum.
Source
Originally published at www.fool.com.